Introduction and Objective: Semaglutide once-weekly(SOW)/Ozempic is used for the management of T2DM and/or obesity (off-label) in Canada. There was a supply shortage of SOW during Oct 2023- Jan 2024. We aimed to explore the glycemic impact, management changes and sentiments related to the shortage.Methods: A phone survey of 159 consenting adults prescribed SOW for T2DM and/or obesityResults: Forty-six (28.9%) said they were affected by the shortage and had to either stop, lower the dose or switch drugs. Those affected were more likely to feel that SOW should be equally accessible to both-those with T2DM and obesity; and had higher shortage-related dissatisfaction. HbA1c was not significantly different between those affected and not affected.Conclusion: Canadians affected by SOW shortage did not feel more strongly that it should only be used for those with T2DM. Glycemic control did not significantly worsen due to the ~4months of drug shortage
A.B. Jain: Advisory Panel; Abbott. Speaker’s Bureau; Abbott. Research Support; Abbott. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Research Support; AstraZeneca, Amgen Inc. Speaker’s Bureau; Amgen Inc. Advisory Panel; Amgen Inc. Research Support; Sanofi. Advisory Panel; Bausch Health. Speaker’s Bureau; Bausch Health. Advisory Panel; Bayer Pharmaceuticals, Inc. Speaker’s Bureau; Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim. Advisory Panel; Dexcom, Inc. Speaker’s Bureau; Dexcom, Inc. Advisory Panel; Eli Lilly and Company. Speaker’s Bureau; Eli Lilly and Company. Advisory Panel; HLS Therapeutics. Speaker’s Bureau; HLS Therapeutics, Medtronic. Advisory Panel; Insulet Corporation. Speaker’s Bureau; Insulet Corporation. Advisory Panel; Sandoz. K. Fan: None. H. Rajpar: None. H. Singh: None. L. Beltran: None.
Source link
Leave a Reply